Sucampo Pharmaceuticals Announces Fourth Quarter and Full Year 2013 Results and Operating Highlights Teleconference and Webcast

Sucampo Pharmaceuticals Announces Fourth Quarter and Full Year 2013 Results
and Operating Highlights Teleconference and Webcast

BETHESDA, Md., Feb. 12, 2014 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc.
(Nasdaq:SCMP) ("Sucampo"), a global biopharmaceutical company, today announced
that it will host a webcast and teleconference with senior management to
discuss its financial results and operating highlights for the fourth quarter
and full year ended December 31, 2013, on Wednesday, February 26, 2014, at
5:00 pm Eastern. The press release announcing the financial results and
operating highlights is expected to be released after the close of the capital
markets that day.

Investors interested in accessing the live audio webcast of the teleconference
may do so at
http://investor.sucampo.com/phoenix.zhtml?c=201197&p=irol-calendar and should
log on 10 to 15 minutes before the teleconference begins in order to download
any software required. Presentation slides will be available via the webcast
link. A replay of the webcast will also be available on Sucampo's website for
several days after the live event. Alternatively, investors may dial
877-280-4955 (domestic) or 857-244-7312 (international) and use passcode
98843095. A replay of the teleconference will be available by dialing
888-286-8010 (domestic) or 617-801-6888 (international), passcode 42236766,
approximately two hours after the teleconference concludes. The archive of the
teleconference will remain available for 30 days.

About Sucampo Pharmaceuticals, Inc.

Sucampo Pharmaceuticals, Inc. is focused on the discovery, development and
commercialization of drugs based on ion channel activators knows as prostones.
Discovered by the company's scientific founder, prostones are naturally
occurring fatty acid metabolites with unique physiological activities. Sucampo
has two marketed products – AMITIZA® and RESCULA® – and a pipeline of
prostone-based product candidates in clinical development. A global company,
Sucampo is headquartered in Bethesda, Maryland, and has operations in Japan,
the United Kingdom and Switzerland. For more information, please visit
www.sucampo.com.

The Sucampo logo and the tagline, The Science of Innovation, are registered
trademarks of Sucampo AG. AMITIZA is a registered trademark of Sucampo AG.
RESCULA is a registered trademark of R-Tech Ueno, Ltd, and has been licensed
to Sucampo AG.

Sucampo Forward-Looking Statement

This press release contains "forward-looking statements" as that term is
defined in the Private Securities Litigation Reform Act of 1995. These
statements are based on management's current expectations and involve risks
and uncertainties, which may cause results to differ materially from those set
forth in the statements. The forward-looking statements may include statements
regarding product development, product potential, future financial and
operating results, and other statements that are not historical facts. The
following factors, among others, could cause actual results to differ from
those set forth in the forward-looking statements: the impact of
pharmaceutical industry regulation and health care legislation; Sucampo's
ability to accurately predict future market conditions; dependence on the
effectiveness of Sucampo's patents and other protections for innovative
products; the risk of new and changing regulation and health policies in the
U.S. and internationally and the exposure to litigation and/or regulatory
actions. No forward-looking statement can be guaranteed and actual results may
differ materially from those projected. Sucampo undertakes no obligation to
publicly update any forward-looking statement, whether as a result of new
information, future events, or otherwise. Forward-looking statements in this
presentation should be evaluated together with the many uncertainties that
affect Sucampo's business, particularly those mentioned in the risk factors
and cautionary statements in Sucampo's most recent Form 8-K and 10-K, which
Sucampo incorporates by reference.

Follow us on Twitter (@Sucampo_Pharma). Follow us on LinkedIn (Sucampo
Pharmaceuticals).

Twitter LinkedIn

CONTACT: Silvia Taylor
         Senior Vice President, Investor Relations PR,
         and Corporate Communications
         1-240-223-3718
         staylor@sucampo.com

Sucampo Logo
 
Press spacebar to pause and continue. Press esc to stop.